"Vancomycin Resistance" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nonsusceptibility of bacteria to the action of VANCOMYCIN, an inhibitor of cell wall synthesis.
| Descriptor ID |
D020713
|
| MeSH Number(s) |
G06.099.225.984 G06.225.347.984 G07.690.773.984.269.347.984
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vancomycin Resistance".
Below are MeSH descriptors whose meaning is more specific than "Vancomycin Resistance".
This graph shows the total number of publications written about "Vancomycin Resistance" by people in this website by year, and whether "Vancomycin Resistance" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2017 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vancomycin Resistance" by people in Profiles.
-
Quantification of the d-Ala-d-Lac-Terminated Peptidoglycan Structure in Vancomycin-Resistant Enterococcus faecalis Using a Combined Solid-State Nuclear Magnetic Resonance and Mass Spectrometry Analysis. Biochemistry. 2017 01 31; 56(4):612-622.
-
Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2013 Oct; 41(5):1039-40.
-
Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84.
-
Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med. 2011 Sep 08; 365(10):892-900.
-
Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer. 2010 Feb 15; 116(4):967-73.
-
Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients. Infect Control Hosp Epidemiol. 2007 Sep; 28(9):1054-9.
-
Impact of surveillance for vancomycin-resistant enterococci on controlling a bloodstream outbreak among patients with hematologic malignancy. Infect Control Hosp Epidemiol. 2004 May; 25(5):391-4.
-
Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother. 2004 Apr; 53(4):646-9.
-
Effectiveness of a multifaceted infection control policy in reducing vancomycin usage and vancomycin-resistant enterococci at a tertiary care cancer centre. J Hosp Infect. 2002 May; 51(1):52-8.
-
Risk factors for vancomycin-resistant Enterococcus (VRE) infection in colonized patients with cancer. Infect Control Hosp Epidemiol. 2002 Feb; 23(2):102-3.